stockrowArcutis Biotherapeutics, Inc.
ARQT Healthcare Biotechnology
Arcutis Biotherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $376.1 million, up 91.3% from fiscal 2024.
- Revenue
- +45.1%
- EPS
- +12.0%
- Free cash flow
- +1,171.9%
- Total debt
- +0.83%
Quarter to September 2026, against a year earlier
Follow ARQT
Alert me
Arcutis Biotherapeutics, Inc. (ARQT) EPS (diluted)
Arcutis Biotherapeutics, Inc.'s EPS (diluted) for fiscal 2025 was −$0.13, compared with −$1.16 in fiscal 2024. Over the twelve months to 30 September 2026 it was $0.21. Over the past ten years it has ranged from −$22.78 (fiscal 2019) to −$0.13 (fiscal 2025) — the current reading is the highest in ten years. EPS (diluted) has risen for 3 consecutive fiscal years. Arcutis Biotherapeutics, Inc. ranks 53rd of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$0.13 | — |
| FY2024 | −$1.16 | — |
| FY2023 | −$3.78 | — |
| FY2022 | −$5.66 | — |
| FY2021 | −$4.18 | — |
| FY2020 | −$3.80 | — |
| FY2019 | −$22.78 | — |
| FY2018 | −$15.53 | — |
| FY2017 | −$7.16 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $0.06 | (41.55%) |
| Jun 2026 | $0.11 | — |
| Mar 2026 | −$0.09 | — |
| Dec 2025 | $0.13 | 116.67% |
| 27 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| ARQT Arcutis Biotherapeutics, Inc. | $0.22 |
| LEGN Legend Biotech Corporation Sponsored ADR compare | −$0.50 |
| IOVA Iovance Biotherapeutics, Inc. compare | −$0.53 |
| ABCL AbCellera Biologics Inc. compare | −$0.54 |
| TNGX Tango Therapeutics, Inc. compare | −$0.85 |
| RLAY Relay Therapeutics, Inc. compare | −$1.57 |
| EWTX Edgewise Therapeutics, Inc. compare | −$1.85 |
| DFTX Definium Therapeutics, Inc. compare | −$3.43 |
| DNTH Dianthus Therapeutics, Inc. compare | −$3.99 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on ARQT
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Altman Z-score
- Beneish M-score
- The full statement